<DOC>
	<DOCNO>NCT02620761</DOCNO>
	<brief_summary>The investigator conduct prospective , blind , randomize , placebo-controlled trial sample size 20 patient two arm ( fenoldopam v placebo ) base upon difference serum creatinine one standard deviation . Fluid salt intake held constant within clinical parameter carefully measure . Fenoldopam start 0.1 ug/kg/min . If , 6 hr decrease blood pressure , dose increase 0.2 ug/kg/min . This dose continue throughout remainder study . A study pediatric patient previously provide FDA show hypotension dose 0.2 ug/kg/min . Fenoldopam start 12 hr first dose indomethacin discontinue 12 hr 3rd dose indomethacin . Study sample include blood urine . The primary outcome reduction renal dysfunction , determine creatinine urine output course treatment . Additional outcome include determination know novel metabolomic urine marker renal dysfunction .</brief_summary>
	<brief_title>Fenoldopam Prevent Renal Dysfunction Indomethacin Treated Preterm Infants</brief_title>
	<detailed_description>Hypotheses - The investigator primary hypothesis fenoldopam reduce renal dysfunction associate indomethacin administration closure patent ductus arteriosus preterm infant . A secondary endpoint measure outcome determination fenoldopam pharmacokinetics premature population . Lastly , investigator hypothesize urine serum acute kidney injury ( AKI ) biomarkers superior contemporary neonatal AKI definition ability identify renal injury . Specific Aims - Evaluate effect fenoldopam renal function preterm infant administer indomethacin - Determination fenoldopam pharmacokinetic pharmacodynamic profile preterm infant - Define whether newly identify biomarkers renal dysfunction sensitive marker renal dysfunction follow indomethacin traditional marker include urine output serum creatinine . Study design - The study prospective , blind , randomize , placebo control trial . Fenoldopam start 0.1 ug/kg/min . If , 6 hr decrease blood pressure , dose increase 0.2 ug/kg/min continue throughout remainder study . The previous study pediatric patient show hypotension dose 0.2 ug/kg/min . Fenoldopam start 12 hr first dose indomethacin discontinue 12 hr 3rd dose indomethacin . Describe study population sample material - 5-14 day old preterm infant bear less equal 28 week gestation patent ductus arteriosus attempt medical closure indomethacin indicate decide upon attend physician Sample size/power primary endpoint - Sample size 20 patient two arm ( fenoldopam v placebo ) base upon improvement serum creatinine one standard deviation .</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Ductus Arteriosus , Patent</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<mesh_term>Fenoldopam</mesh_term>
	<criteria>1 . Gestational age birth 23 0/7 27 6/7 week best obstetrical date 2 . Postnatal age 5 14 day 3 . No known congenital abnormality involve kidney , heart lung 4 . No preexist renal dysfunction , define serum creatinine &gt; 1.0 mg/dl , urine output &lt; 1.0 ml/kg/hour previous 24 hour . 1 . Enrollment concurrent study intervention may contribute confound variable compete outcomes 2 . Infants antenatally postnatally diagnosed renal urinary tract abnormalities 3 . Infants umbilical cord infant blood pH 7.0 time enrollment 4 . Attending physician unwilling infant participate study 5 . Absence inform consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Days</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>